Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018

Published: June 2014
No. of Pages: 250
   

Several initiatives and healthcare reforms have been developed in order to support the adoption of human insulin among diabetic population as diabetes will be the seventh leading cause of mortality by 2030. WHO and IDF began joint initiative to reduce the impact of diabetes and related chronic conditions on the health of children and adults worldwide. Apart from this, the U.S. government has now started taking various initiatives to boost its biosimilars market. In 2013, Obama’s administration sponsored a budget of $4.5 billion, an increase of 17% over 2012, to FDA in order to support the review of generics and biosimilars. The funding would mostly come from user fees paid by drug makers. More than $364 million will be allocated to support generic drug activities and development of biosimilars, out of which $20 million will be allocated to the FDA for biosimilars.

Modern human insulin accounted for the largest share -84%- of global human insulin market. Premixed modern human insulin and long acting human insulin are estimated to grow at a brisk pace over the next five years. The high growth in these segments can be attributed to the growing demand of Apidra, Lantus, and Levemir. Furthermore, these drugs reported high efficiency and effectiveness as compared to other synthetic insulin, animal insulin, and other human insulin.

New technologies such as safety pen needles and infusion pumps have emerged as efficient mode of delivery for human insulin. Pen needles offer significant benefits to the healthcare sector. The usage of easy to fit needles is rising due to the convenience offered by them. These needles are easy to attach, remove, and dispose, thus they can be easily used by patients with manual dexterity problems, and visual impairment. Diabetes educators and clinicians across the world recommend the usage of needles with shorter lengths and higher gauge sizes for convenience and to minimize pain. Owing to these factors, technological advancement is expected to be a major revenue pocket for the human insulin market in the coming years.

Countries such as China, India, Japan, and Korea will also offer potential growth opportunities to human insulin market. Of all the countries, China is estimated to be the fastest growing market for human insulin market. Saudi Arabia, Qatar, Egypt, U.A.E, and Brazil will also emerge as lucrative markets for human insulin market.

Above all, most of the early biologic human insulin lost their patent protection in the first half of the 20th century, while many of the current best-selling drugs such as insulin glargine, insulin as part, and insulin lispro are all set to lose their patent protection in the coming years. This creates new opportunities for biosimilar drugs which is estimated to grow at a CAGR of 35% from 2014-2019.

The grey area while estimating the market size is the variable price of human insulin across the globe as it differs widely across each country.

From an insight perspective, this research report focuses on the qualitative data, market size, share, and growth of various segments and sub-segments, competitive landscape, and company profiles.

The qualitative data covers various levels of industry analysis, such as market dynamics (drivers, restraints, opportunities, and threats), and porter’s five forces analysis at global level. The report also offers market shares, sizes, and related growth of various segments in the industry. It also focuses on the emerging and high-growth segments of human insulin market (Biosimilars of human insulin, long acting human insulin, and premixed human insulin), high-growth regions (Asia-Pacific), and the initiatives of their respective governments.

The competitive landscape covers the growth strategies adopted by industry players in the last three years. The company profiles comprise the basic views on the key players in the human insulin market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018

Table of Contents

1 Introduction
1.1 Objective of the Study
1.2 Report Description
1.3 Market Scope
1.4 Stakeholders
1.5 Research Methodology
1.6 Market Size Estimation
1.7 Market Crackdown and Data Triangulation
1.8 Market Forecasting Model
1.9 Key Data Point Taken From Secondary & Primary Sources

2 Executive Summary

3 Premium Insights

4 Market Overview
4.1 Introduction
4.2 History
4.3 Market Segmentation
4.4 Market Dynamics
4.4.1 Drivers
4.4.1.1 Rising incidences of Diabetic Population
4.4.1.2 Increasing Aging Population
4.4.1.3 Growing Prevalence of Lifestyle Induced Disorder Such As Obesity
4.4.1.4 off-Patent Biologic Drugs Enhance the Demand of Biosimilar
4.4.1.5 Rising Demand for Biosimilar Drugs Due to Its Cost-Effectiveness
4.4.1.6 Government Support Amd Initiatives
4.4.1.7 R&D Initiatives Aimed At Developing New Products
4.4.1.8 Growing Demand for Insulin Analogues
4.4.1.9 Technological Advancements
4.4.2 Restrains
4.4.2.1 Stringent Regulatory Environment
4.4.2.2 High Manufacturing Complexities and Cost of Production
4.4.3 Opportunities
4.4.3.1 Untapped Emerging Market
4.4.3.2 Pipeline Products
4.4.4 Challenges
4.4.1.1 Requirement of Complex Infrastructure for Manufacturing and Extensive Clinical Trails for Approvals
4.5 Burning Issues
4.5.1 Product Recall
4.6 Winning Imperative
4.6.1 Collaborations & Agreements to Gain  Competitive Edge

5 Human Insulin Market, By Types
5.1 Introduction
5.2 Traditional Human Insulin
5.1.1 Short Acting Human Insulin
5.1.2 Intermediate Acting Human Insulin
5.1.3 Premixed Traditional Human Insulin
5.2 Modern Human Insulin
5.2.1 Rapid Acting Human Insulin
5.2.2 Long Acting Human Insulin
5.2.3 Premixed Modern Human Insulin

6 Human Insulin Market, By Brand
6.1 Introduction
6.1 Traditional Human Insulin,By Brand
6.1.1 Actrapid, Mixtard, Insulatard
6.1.2 Humulin
6.1.3 Insum,An
6.2 Modern Human Insulin, By Brand
6.2.1 Lantus
6.2.2 Novorapid/Novolog
6.2.3 Humalog
6.2.4 Levemir
6.2.5 Novomix
6.2.6 Apidra
6.2.7 Tresiba

7 Human Insulin Market, By Geography
7.1  North America
7.1.1 U.S.
7.1.2 Canada
7.2  Europe
7.2.1 U.K.
7.2.2 Germany
7.2.3 France
7.2.4 Italy
7.2.5 Spain
7.2.6  Rest of Europe
7.3 Asia-Pacific
7.3.1  Japan
7.3.2  China
7.3.3 India
7.3.4 Korea, Australia,& Rest of Asia
7.5 Rest of the World (Row)
7.5.1 Latin America
7.5.2 Middle East
7.5.3 Africa

8 Competitive Landscape
8.1 New Product Launches
8.2 Agreements/Partnerships/Collaborations/Joint Ventures
8.3 Mergers and Acquisitions
8.4 Other Developments

9 Company Profiles
9.1 Novo Nordisk
9.1.1 Business Overview
9.1.2 Key Financials
9.1.3 Products
9.1.4 Pipeline Products
9.1.5 Strategy
9.1.6 Developments
9.1.7 MNM View
9.2 EliLilly
9.3 Sanofi Aventis
9.4 Biocon
9.5 Julphar Pharmaceuticals

List of Tables

Table 1 Global Human Insulin Market, By Volume ,2014-2019 (Tmu)
Table 2 Global Traditional Human Insulin Market, By Product, 2012–2019 ($Million)
Table 3 Global Traditional Human Insulin Market, By Geography,  2012–2019 ($Million
Table 4 Global Short Acting Human Insulin Market, By Geography, 2012–2019 ($Million)
Table 5 Global Intermediate Acting Human Insulin Market, By Geography, 2012–2019 ($Million)
Table 6 Global Premixed Human Insulin Market, By Geography,2012-2019
Table 7 Global Modern Human Insulin Market, By Product,2012-2019($Million)
Table 8 Global Modern Human Insulin Market, By Geography,2012-2019($Million)
Table 9 Global Rapid Acting Human Insulin Market, By Geography, 2012–2019 ($Million
Table 10 Global Long Acting Human Insulin Market, By Geography, 2012–2019 ($Million
Table 11 Global Premixed Insulin Market, By Geography, 2012–2019 ($Million)
Table 12 Global Traditional Human Insulin Market, By Brand, 2012–2019 ($Million
Table 13 Global Humulin Market, By Geography, 2012–2019 ($Million)
Table 14 Global Actrapid, Mixtard, & Insulatard Market, By Geography, 2012–2019 ($Million
Table 15 Global Insuman Market, By Geography, 2012–2019 ($Million)
Table 16 Global Modern Human Insulin Market, By Brand, 2012–2019 ($Million)
Table 17 Global Lantus Market, By Geography, 2012–2019 ($Million)
Table 18 Global Novorapid/Novolog Market, By Geography, 2012–2019 ($Million)
Table 19 Global Humalog Market, By Geography, 2012–2019 ($Million)
Table 20 Global Levemir Market, By Geography, 2012–2019 ($Million)
Table 21 Global Novomix Market, By Geography, 2012–2019 ($Million
Table 22 Global Apidra Market, By Geography, 2012–2019 ($Million)
Table 23 Global Tresiba Market, By Geography, 2012–2019 ($Million)
Table 24 Global Human Insulin Market, By Geography ,2014-2019 ($Million)
Table 25 Global Human Insulin Market, By Country ,2014-2019 ($Million)
Table 26 Global Short Acting Human Insulin Market, By Country ,2014-2019 ($Million)
Table 27 Global Intermediate Acting Human Insulin Market, By Country ,2014-2019 ($Million)
Table 28 Global Premixed Traditioanl Human Insulin Market, By Country ,2014-2019 ($Million)
Table 29 Global Long Acting Human Insulin Market, By Country ,2014-2019 ($Million)
Table 30 Global Rapid Acting Human Insulin Market, By Country ,2014-2019 ($Million)
Table 31 Global Premixed Modern Human Insulin Market, By Country ,2014-2019 ($Million)
Table 32 North America, Diabetes Prevalence Rate (2010-2030)
Table 33 North America  off-Patent Human Insulin Product
Table 34 North America: Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 35 North America: Traditional Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 36 North America: Modern Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 37 North America: Traditional Human Insulin Market, By  Brands,2014-2019 ($Million)
Table 38 North America: Modern Human Insulin Market, By  Brands,2014-2019 ($Million)
Table 39 North America: Traditional Human Insulin Market, By  Country, 2014-2019 ($Million)
Table 40 North America: Modern Human Insulin Market, By  2014-2019 ($Million)
Table 41 U.S.: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 42 Canada: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 43 North America: Short Human Insulin Market, By  Country,2014-2019 ($Million)
Table 44 North America: Intermediate Acting Human Insulin Market, By  Country,2014-2019 ($Million)
Table 45 North America: Premixed Traditional Human Insulin Market, By  Country,2014-2019 ($Million)
Table 46 North America: Long Acting Human Insulin Market, By  Country,2014-2019 ($Million)
Table 47 North America: Rapid Acting Human Insulin Market, By  Country,2014-2019 ($Million)
Table 48 North America: Premixed Modern Human Insulin Market, By  Country,2014-2019 ($Million
Table 49 Europe, Diabetes Prevalence Rate (2010-2030)
Table 50 Europe: off-Patent Human Insulin Product
Table 51 Europe: Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 52 Europe: Traditional Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 53 Europe: Modern Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 54 Europe: Traditional Human Insulin Market, By  Brands,2014-2019 ($Million)
Table 55 Europe: Modern Human Insulin Market, By  Brands,2014-2019 ($Million)
Table 56 Europe: Traditional Human Insulin Market, By  Country, 2014-2019 ($Million)
Table 57 Europe: Modern Human Insulin Market, By 2014-2019 ($Million)
Table 58 Germany: Human Insulin Market, By Product,2014-2019 ($Million)
Table 59 France: Human Insulin Market, By Product,2014-2019 ($Million)
Table 60 U.K.: Human Insulin Market, By Product,2014-2019 ($Million)
Table 61 Italy: Human Insulin Market, By Product,2014-2019 ($Million)
Table 62 Spain: Human Insulin Market, By Product,2014-2019 ($Million)
Table 63 ROE: Human Insulin Market, By Product,2014-2019 ($Million)
Table 64 Europe: Short Human Insulin Market, By  Country,2014-2019 ($Million)
Table 65 Europe: Intermediate Acting Human Insulin Market, By  Country,2014-2019 ($Million)
Table 66 Europe: Premixed Traditional Human Insulin Market, By  Country,2014-2019 ($Million)
Table 67 Europe: Long Acting Human Insulin Market, By Country,2014-2019 ($Million)
Table 68 Europe: Rapid Acting Human Insulin Market, By Country,2014-2019 ($Million)
Table 69 Europe: Premixed Modern Human Insulin Market, By  Country,2014-2019 ($Million
Table 70 Asia-Pacific, Diabetes Prevalence Rate (2010-2030)
Table 71 Asia-Pacific: off-Patent Human Insulin Product
Table 72 Asia-Pacific: Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 73 Asia-Pacific: Traditional Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 74 Asia-Pacific: Modern Human Insulin Market, By Products ,2014-2019 ($Million)
Table 75 Asia-Pacific: Traditional Human Insulin Market,By  Brands,2014-2019 ($Million)
Table 76 Asia-Pacific: Modern Human Insulin Market, By  Brands,2014-2019 ($Million)
Table 77 Asia-Pacific: Traditional Human Insulin Market,By  Country, 2014-2019 ($Million)
Table 78 Asia-Pacific: Modern Human Insulin Market, By  Country,2014-2019 ($Million)
Table 79 Japan: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 80 China: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 81 India: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 82 Australia: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 83 Korea: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 84 ROA: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 85 Asia-Pacific: Short Human Insulin Market, By  Country,2014-2019 ($Million)
Table 86 Asia-Pacific: Intermediate Acting Human Insulin Market, By  Country,2014-2019 ($Million)
Table 87 Asia-Pacific: Premixed Traditional Human Insulin Market, By  Country,2014-2019 ($Million)
Table 88 Asia-Pacific: Long Acting Human Insulin Market, By  Country,2014-2019 ($Million)
Table 89 Asia-Pacific: Rapid Acting Human Insulin Market, By  Country,2014-2019 ($Million)
Table 90 Asia-Pacific: Premixed Modern Human Insulin Market, By  Country,2014-2019 ($Million
Table 91 ROW, Diabetes Prevalence Rate (2010-2030)
Table 92 ROW: off-Patent Human Insulin Product
Table 93 ROW: Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 94 ROW: Traditional Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 95 ROW: Modern Human Insulin Market, By  Products ,2014-2019 ($Million)
Table 96 ROW: Traditional Human Insulin Market, By  Brands,2014-2019 ($Million)
Table 97 ROW: Modern Human Insulin Market, By  Brands,2014-2019 ($Million)
Table 98 ROW: Traditional Human Insulin Market, By  Country, 2014-2019 ($Million)
Table 99 ROW: Modern Human Insulin Market, By  2014-2019 ($Million)
Table 100 Latin America: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 101 Middle East: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 102 Africa: Human Insulin Market, By  Product,2014-2019 ($Million)
Table 103 ROW: Short Human Insulin Market, By  Country,2014-2019 ($Million)
Table 104 ROW: Intermediate Acting Human Insulin Market, By  Country,2014-2019 ($Million)
Table 105 ROW: Premixed Traditional Human Insulin Market, By  Country,2014-2019 ($Million)
Table 106 ROW: Long Acting Human Insulin Market, By  Country,2014-2019 ($Million)
Table 107 ROW: Rapid Acting Human Insulin Market, By  Country,2014-2019 ($Million)
Table 108 ROW: Premixed Modern Human Insulin Market, By  Country,2014-2019 ($Million
Table 109 New Product Launches & Product Modifications, 2011–2014
Table 110 Agreements, Partnerships & Collaborations, 2011–2014
Table 111 Mergers & Acquisitions, 2011–2014
Table 112 New Product Approval,2011-2014

List of Figures

Figure 1 Research Methodology
Figure 2 Market Size Estimation Methodology
Figure 3 Data Triangulation Methodology
Figure 4 Biologic Vs. Biosimilar Human Insulin: Market Size forecast, 2011–2018
Figure 5 Human Insulin Market, Traditional Vs. Modern Human Insulin,2014-2019 ($Million)
Figure 6 Human Insulin Market, Biologics Vs. Biosimilar,2014-2019 ($Million)
Figure 7 Human Insulin Market, By Brands,2014-2019 ($Million
Figure 8 Human Insulin Market,Sub Segment of Biopharmaceutical Market
Figure 9 Human Insulin Market Snapshot,2013($Million)
Figure 10 Human Analysis Market,Geographic Analysis,By Product,2013($Million)
Figure 11 Market Dynamics : Human Insulin Market
Figure 12 Opportunity Matrix: Global Human Insulin Market, By Brands,2013
Figure 13 Human Insulin Timeline
Figure 14 Human Insulin,Market Segmentation
Figure 15 Market Share Analysis, By Key Players
Figure 16 Prther's Five force Analysis
Figure 17 Major Potential Market
Figure 18 Modern Human Insulin Market, By Types, 2014 Vs 2019 ($Million
Figure 19 Traditional Human Insulin Market, By Brand, 2014 Vs2019 ($Million
Figure 20 Modern Human Insulin Market, By Brand, 2014 Vs 2019 ($Million
Figure 21 Opportunity Matrix; Human Insulin Market , By Geography ,2014
Figure 22 Opportunity Matrix : Human Insulin Market, By Country ,2014
Figure 23 Key Growth Strategies, 2011-2014
Figure 24 Novo Nordisk: Geographic Presence (Manufacturing Unit)
Figure 25 Novo Nordisk: Financials, 2011-2013($Million)
Figure 26 Novo Nordisk: Buisness Revenue Mix,2013,($Million)
Figure 27 Novo Nordisk: Geographic Revenue Mix,2013,($Million)
Figure 28 Eli Lilly: Geographic Presence (Manufacturing Unit)
Figure 29 Eli Lilly: Financials, 2011-2013($Million)
Figure 30 Eli Lilly: Buisness Revenue Mix,2013,($Million)
Figure 31 Eli Lilly: Geographic Revenue Mix,2013,($Million)
Figure 32 Sanofi Aventis : Geographic Presence (Manufacturing Unit)
Figure 33 Sanofi Aventis: Financials, 2011-2013($Million)
Figure 34 Sanofi Aventis: Buisness Revenue Mix,2013,($Million)
Figure 35 Sanofi Aventis: Geographic Revenue Mix,2013,($Million)
Figure 36 Biocon : Geographic Presence (Manufacturing Unit)
Figure 37 Biocon: Financials, 2011-2013($Million)
Figure 38 Biocon: Buisness Revenue Mix,2013,($Million)
Figure 39 Biocon: Geographic Revenue Mix,2013,($Million)
Figure 40 Julphar Pharmaceuticals : Geographic Presence (Manufacturing Unit)
Figure 41 Julphar Pharmaceuticals: Financials, 2011-2013($Million)
Figure 42 Julphar Pharmaceuticals: Buisness Revenue Mix,2013,($Million)
Figure 43 Julphar Pharmaceuticals: Geographic Revenue Mix,2013,($Million)

Published By: MarketsandMarkets
Product Code: MarketsandMarkets1941


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100